Ernexa Therapeutics Inc. (ERNA)
| Market Cap | 14.16M +9.5% |
| Revenue (ttm) | n/a |
| Net Income | -11.40M |
| EPS | -27.49 |
| Shares Out | 1.17M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,781,916 |
| Open | 14.37 |
| Previous Close | 12.01 |
| Day's Range | 11.70 - 14.59 |
| 52-Week Range | 3.18 - 100.46 |
| Beta | 1.89 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 26, 2026 |
About ERNA
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company’s lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutic... [Read more]
Financial Performance
Financial StatementsNews
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101
Moderated discussion with Chief Scientific Officer Dr. Robert Pierce on ovarian cancer and evolving treatment landscape
Ernexa Therapeutics initiated with a Buy at Brookline
Brookline initiated coverage of Ernexa Therapeutics (ERNA) with a Buy rating and $30 price target Ernexa is engineering induced pluripotent stem cells and transforming them into induced mesenchymal st...
3 Penny Stocks to Watch Now, 5/7/26
Ernexa Therapeutics ($ERNA), Powell Max Limited ($PMAX), and Ambitions Enterprise Management Co. ($AHMA) are the three penny stocks to watch on May 7, according to TipRanks’ Penny Stock Screener tool.
Ernexa Therapeutics announces new ERNA-101 preclinical data
Ernexa Therapeutics (ERNA) announced new preclinical data demonstrating that its lead cell therapy candidate, ERNA-101, in combination with PD-1 blockade, drives complete tumor clearance and 100% long...
Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models
CAMBRIDGE, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease...
Ernexa Therapeutics announces 1-for-25 reverse stock split
Ernexa Therapeutics announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share, at a ratio of 1-for-25, effective May 4 at…
Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split
CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disea...
Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026
Preclinical data demonstrate deep and durable tumor regressions with lead product candidate ERNA-101 in combination with PD-1 Blockade in ovarian cancer
Ernexa Therapeutics files $50M mixed securities shelf
06:51 EDT Ernexa Therapeutics (ERNA) files $50M mixed securities shelf
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
Live video webcast with Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, on Wednesday, February 25th at 4:00 PM ET
Ernexa Therapeutics prices 21M shares at 50c in public offering
Ernexa Therapeutics (ERNA) announced the pricing of a best-efforts registered public offering of 21,000,000 shares of its common stock and warrants to purchase up to 21,000,000 shares of common stock,...
Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering
CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics Inc. (Nasdaq: ERNA) (“Ernexa” or the “Company”), an industry innovator developing novel cell therapies for the treatment of adva...
Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA
Access the “What This Means” segment here
Ernexa Therapeutics files to sell common stock, warrants, no amount given
Brookline Capital Markets, a division of Arcadia Securities, is exclusive placement agent for the offering.
Ernexa selected as company for JETRO Japan entry acceleration program
Ernexa Therapeutics (ERNA) announced it has been selected as one of only ten companies worldwide to participate in the Japan Entry Acceleration Program, JEAP, an initiative launched by the Japan…
Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program
CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune diseas...
Ernexa Therapeutics completes Pre-IND meeting with FDA
Ernexa Therapeutics (ERNA) announced the completion of its recent Pre-Investigational New Drug Application meeting with the U.S. Food and Drug Administration. Feedback from the FDA provided strong reg...
Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer
Regulatory alignment supports rapid progress, tech transfer already underway to accelerate clinical readiness Company on track to initiate first-in-human (FIH) trial for the treatment of ovarian cance...
Ernexa Therapeutics presents preclinical data at ASH meeting on ERNA-101
Ernexa Therapeutics (ERNA) announced the presentation of new preclinical data on its lead cell therapy candidate, ERNA-101, at the American Society of Hematology, ASH, Annual Meeting. The data demonst...
Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer
Positive results of ERNA-101 in ovarian cancer models demonstrated promising survival benefit and immune activation, underscoring the potential for broad oncology applications, including hematologic m...
Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting
CAMBRIDGE, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune diseas...
Ernexa Therapeutics appoints Ira Winer to Scientific, Medical Advisory Board
Ernexa announced the appointment of Dr. Ira Winer to its Scientific and Medical Advisory Board. Winer serves as a Professor in the Department of Oncology at Wayne State University School…
Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D.
Appointment reinforces clinical and translational depth as Ernexa advances its best-in-class iMSC cell therapy platform into first-in-human trials Appointment reinforces clinical and translational dep...
Ernexa Therapeutics to Present at Oxford Global's Cell 2025
CAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune diseas...
Ernexa Therapeutics reports Q3 operating loss $2M vs $2.3M last year
“We continue to operate with financial discipline, focusing our resources on advancing our cell therapy programs toward the clinical stage,” said Sanjeev Luther, President and CEO of Ernexa Therapeuti...